Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK And Angiochem In Rare-Diseases Pact
by Lisa M. Jarvis
March 5, 2012
| A version of this story appeared in
Volume 90, Issue 10
To bolster its rare-diseases program, GlaxoSmithKline is teaming up with Montreal-based Angiochem to develop treatments for lysosomal storage diseases. Angiochem gets an up-front payment of as much as $31.5 million plus research funding it will use to develop enzyme replacement therapies (ERTs) that can cross the blood-brain barrier. Current ERTs are unable to address the neurological symptoms caused by lysosomal storage diseases. Angiochem’s engineered-peptide technology overcomes those limitations by binding to the LRP1 receptor, which provides a gateway into the brain.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter